Core Viewpoint - Guardian Pharmacy Services (GRDN) is expected to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook being crucial for assessing the company's earnings picture [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to show quarterly earnings of $0.24 per share, reflecting a +112% change year-over-year, and revenues are projected to be $353.95 million, up 12.6% from the previous year [3]. - The earnings report is scheduled for November 10, and stock movement may depend on whether the actual results exceed or fall short of these expectations [2]. Estimate Revisions - The consensus EPS estimate has been revised 2.04% lower in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4][12]. - The Most Accurate Estimate for Guardian Pharmacy is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.82%, suggesting a bearish outlook from analysts [12]. Earnings Surprise History - In the last reported quarter, Guardian Pharmacy was expected to post earnings of $0.22 per share but delivered $0.23, resulting in a surprise of +4.55% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates two times [14]. Industry Comparison - Nektar Therapeutics (NKTR), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $2.85 per share, indicating a year-over-year change of -5.6%, with revenues expected to decline by 56.1% [18][19]. - Nektar's consensus EPS estimate has been revised 2.6% higher recently, and it has a positive Earnings ESP of +18.72%, combined with a Zacks Rank of 2 (Buy), indicating a likely earnings beat [19][20].
Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release